Technological Advances in Bifidobacterial Molecular Genetics: Application to Functional Genomics and Medical Treatments

• Published in: Bioscience of Microbiota, Food and Health Vol. 31; no. 2; pp. 15 - 25
• Main Authors: FUKIYA, Satoru, HIRAYAMA, Yosuke, SAKANAKA, Mikiyasu, KANO, Yasunobu, YOKOTA, Atsushi
• Format: Journal Article
• Language: English; Japanese
• Published: Japan BMFH Press 01.01.2012; Bioscience of Microbiota, Food and Health
• Subjects: Bifidobacterium; cryptic plasmid; enzyme/prodrug therapy; Escherichia; functional genomics; heterologous gene expression; molecular genetics; Review; targeted gene inactivation; molecular genetics; cryptic plasmid; Bifidobacterium; heterologous gene expression; functional genomics; targeted gene inactivation; enzyme/prodrug therapy
• ISSN: 2186-6953; 2186-3342; 2186-3342
• DOI: 10.12938/bmfh.31.15

Bifidobacteria are well known as beneficial intestinal bacteria that exert health-promoting effects in humans. In addition to physiological and immunological investigations, molecular genetic technologies have been developed and have recently started to be applied to clarify the molecular bases of host-Bifidobacterium interactions. These technologies include transformation technologies and Escherichia coli-Bifidobacterium shuttle vectors that enable heterologous gene expression. In this context, a plasmid artificial modification method that protects the introduced plasmid from the restriction system in host bifidobacteria has recently been developed to increase transformation efficiency. On the other hand, targeted gene inactivation systems, which are vital for functional genomics, seemed far from being practically applicable in bifidobacteria. However, remarkable progress in this technology has recently been achieved, enabling functional genomics in bifidobacteria. Integrated use of these molecular genetic technologies with omics-based analyses will surely boost characterization of the molecular basis underlying beneficial effects of bifidobacteria. Applications of recombinant bifidobacteria to medical treatments have also progressed.